INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer and is a leading cause of cancer death worldwide. 1 The majority of newly diagnosed patients present with local or regional disease 2 and can potentially be cured by a combination of surgery and chemotherapy. However, differences in clinical outcomes exist that depend on tumor biology. CRCs can be divided into those with microsatellite instability (MSI) and those that are microsatellite stable but show chromosomal instability. MSI is a consequence of deficient DNA mismatch repair (dMMR) 3,4 that results in an accumulation of errors within microsatellite regions producing high mutation rates. Most MSI/dMMR CRCs are sporadic and are associated with the CpG island methylator phenotype (CIMP) 5, 6 and have frequent BRAF V600E mutations. 7 The BRAF oncogene encodes a serine/ threonine kinase and is a downstream effector of the Ras/Raf/MAPK signaling pathway. 8, 9 BRAF V600E or KRAS mutations predict nonresponse to anti-epidermal growth factor receptor antibody therapy in metastatic CRCs, although only KRAS has been validated. 10 In metastatic CRCs, BRAF V600E mutations 11 have been associated with adverse clinical outcome. 12 
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CRCs with MSI/dMMR have distinct clinicopathologic features including a propensity for the proximal colon. 13, 14 Most studies have shown that MSI/dMMR is associated with a favorable prognosis in patients with CRC.
14-17 An important limitation of these studies is that patients were not treated with the current standard adjuvant chemotherapy regimen of fluorouracil (FU), leucovorin, and oxaliplatin (FOLFOX) . 18 This issue is complex in that MSI/dMMR is associated with resistance to FU in vitro 19 and in vivo, 20, 21 whereas in vitro chemotherapy sensitivity to oxaliplatin seems to be independent of the mismatch repair (MMR) system. 22 We determined the association of MMR status with disease-free survival (DFS) in prospectively collected, stage III colon carcinomas from patients treated in a phase III trial of FOLFOX alone or combined with cetuximab as adjuvant chemotherapy (North Central Cancer Treatment Group N0147 trial). 23 In this trial, the addition of cetuximab to FOLFOX failed to improve DFS overall or in patients with wild-type KRAS tumors. 23 We examined the prognostic impact of MMR on DFS adjusting for the mutation status of BRAF V600E or KRAS genes. Given that dMMR tumors are located primarily in the proximal colon and show a reduced propensity for metastases, [24] [25] [26] we also examined the prognostic impact of MMR stratified by tumor site and lymph node category (N1 v N2). An independent cohort of patients with stage III colon cancer from another phase III adjuvant study was used for validation.
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PATIENTS AND METHODS
Study Population
Patients (N ϭ 2,686) with resected, stage III (any T, N1 or N2, M0) adenocarcinoma of the colon participated in a phase III randomized trial of modified FOLFOX6 (n ϭ 1,337) or modified FOLFOX6 ϩ cetuximab (n ϭ 1,349). 23 The trial was modified after initiation to restrict random assignment to patients whose tumors expressed wild-type KRAS.
23 Biospecimens were prospectively collected and required for study participation. A central pathology review was performed. Patients received chemotherapy within 10 weeks of surgery. Stratification factors included the following: number of metastatic lymph nodes (one to three v Ն four nodes), histologic grade (high [poorly differentiated or undifferentiated] v low [well or moderately differentiated]), and T stage (T1-2 v T3 v T4). Proximal tumor sites included cecum and ascending and transverse colon; distal sites included splenic flexure and descending and sigmoid colon. The study was approved by the Mayo Clinic Institutional Review Board and the North Central Cancer Treatment Group (now part of Alliance for Clinical Trials in Oncology).
DNA MMR Proteins
MMR protein (MLH1, MSH2, and MSH6) expression was analyzed in formalin-fixed, paraffin-embedded tumor sections using an immunoperoxidase method. 28 Monoclonal antibodies included mouse antihuman MLH1 (clone G168-15; Biocare Medical, Concord, CA), antihuman MSH2 (clone FE11; Biocare Medical), and antihuman MSH6 (clone BC/44; Biocare Medical). MMR protein loss was defined as the absence of nuclear staining in tumor cells in the presence of positive nuclear staining in normal colonic epithelium and lymphocytes. Expression was scored by one GI pathologist (T.C.S.). Tumors were classified as dMMR (v proficient MMR [pMMR]) if loss of one or more MMR proteins was detected.
BRAF and KRAS Gene Mutations
Mutation status was determined using genomic DNA extracted from macrodissected tumor tissue. Testing for the BRAF V600E hotspot mutation in exon 15 was performed using a multiplex allele-specific, real-time polymerase chain reaction-based assay and an automated sequencing technique. 29 Primer sequences included the following: wild-type forward, NED-TGATTTTGGT-CATGCTACAGT; mutant forward, 6-Fam-CAGTGATTTTGCTCTAGCT TCAGA; and reverse, GTTTCTTTCTAGTAACTCAGCAGC. KRAS mutation status was analyzed in extracted DNA using the DxS mutation test kit KR-03/04 (DxS, Manchester, United Kingdom), assessing for seven different mutations in codons 12 and 13.
30 For both genes, mutational analysis was performed in a Clinical Laboratory Improvement Amendments-compliant laboratory at the Mayo Clinic. All biomarker data were analyzed with investigators blinded to patient outcomes.
Validation Cohort
The validation cohort consisted of patients with stage III colon cancer (N ϭ 1,264) randomly assigned to receive FU plus leucovorin or FU, leucovorin, and irinotecan as adjuvant chemotherapy (Cancer and Leukemia Group B [CALGB] 89803 trial). 27 No differences in survival were observed between the treatment arms. MMR status was retrospectively determined in available tissues (n ϭ 891) by analysis of MLH1 and MSH2 protein expression and/or by MSI, as previously described. 27 The mutation status of KRAS and BRAF V600E was previously analyzed in a subset (n ϭ 571) of the cohort.
31,32
Statistical Analysis Analysis of the primary study end point of DFS was previously reported for the treatment arms. 23 All patients were censored for DFS at 5 years after random assignment; intent-to-treat principles were used. The two treatment arms were pooled given the lack of statistically significant differences in DFS rates and the lack of significant interactions between any of the biomarkers and treatment. Median follow-up time for 2,213 surviving patients was 4.1 years (range, 0.0 to 7.5 years). Kaplan-Meier methods were used to describe the distributions of DFS. 33 Univariate Cox proportional hazards models 34 were used to explore the associations of patient characteristics and biomarkers with outcome. Thereafter, multivariable models were used, and unless otherwise specified, all models were adjusted for stratification factors (T stage, nodal category, and grade), primary tumor site, age, sex, treatment, and status of MMR, BRAF V600E , or KRAS. Interactions between biomarkers or biomarkers with treatment were assessed. Analyses were reported using a validation cohort and to evaluate the robustness of the results. Two-sided P values are reported; P Ͻ .05 was considered statistically significant. Analyses were performed using SAS version 9.2 (SAS Institute, Cary NC) and R version 2.14.
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RESULTS
Study Population and Biomarkers
Characteristics of the patient population with stage III colon carcinomas (N ϭ 2,686) are listed in Table 1 , or KRAS status. In the full cohort, dMMR was detected in 314 (12%) of 2,580 tumors, and mutations were present in BRAF V600E or KRAS in 14% (346 of 2,515 tumors) and 28% (716 of 2,579 tumors), respectively ( Table 1) . Of note, our clinical trial population was enriched with wild-type KRAS tumors based on study eligibility criteria. 23 BRAF V600E and KRAS mutations were mutually exclusive. The number of cancers located in the proximal or distal colon was equal in the study population. Patients with proximal versus distal tumors were significantly older (median age, 61 v 56 years, respectively; P Ͻ .001) and more often women, and their tumors were more likely to have high histologic grade and increased T stage (T4 v T3 v T1-2; all P Ͻ .02; Table 1 ). Furthermore, proximal versus distal cancers were significantly more likely to show dMMR (21% v 2.8%, respectively; P Ͻ .001) and mutations in BRAF V600E (23.3% v 4.3%, respectively; P Ͻ .001) or KRAS (32.8% v 22.6%, respectively; P Ͻ .001; Table 1 ).
DNA MMR Status
dMMR was detected in 12% of tumors that exhibited loss of MLH1 (n ϭ 264; 84%), MSH2 (n ϭ 46), or MSH6 (n ϭ 53) protein mutations were significantly more frequent in N2 versus N1 tumors (P Ͻ .001). KRAS mutations were detected in only 4.7% of dMMR tumors (P Ͻ .001) and were significantly associated with proximal site, low-grade histology, and N1 stage (all P Ͻ .02; Table 1 ).
Prognostic Impact of Clinicopathologic Variables and Biomarkers
Proximal tumor site and higher T or N stage were each significantly associated with inferior DFS and were independent of other covariates ( , or KRAS status (HR, 0.82; 95% CI, 0.64 to 1.07; P ϭ .14; Fig 1) . Mutated versus wild-type BRAF V600E and KRAS were each significantly associated with worse DFS in univariate and multivariate analyses (Table 2 ; Fig 1) .
Analysis of MMR status by tumor site revealed that dMMR versus pMMR tumors in the proximal colon were associated with better DFS (HR, 0.78; 95% CI, 0.61 to 1.00; P ϭ .053); this association was statistically significant after adjustment for BRAF V600E , KRAS, and clinicopathologic variables (HR, 0.71; 95% CI, 0.53 to 0.94; P ϭ .018; Fig 2) . In contrast, dMMR versus pMMR tumors in the distal colon were associated with significantly worse DFS by univariate analysis (HR, 1.91; 95% CI, 1.11 to 3.26; P ϭ .018); this association was marginally significant in a multivariable analysis (HR, 1.71; 95% CI, 0.99 to 2.95; P ϭ .056; Fig 2) . Consistent with these findings, we found a statistically significant interaction between MMR status and primary tumor site (P interaction ϭ .0089; Table 2 ). Within MMR categories, pMMR tumors of the proximal versus distal colon were associated with a significantly worse DFS (adjusted HR, 1.27; 95% CI, 1.08 to 1.52; P ϭ .0047).
Among patients with dMMR, those with N2 versus N1 disease had significantly worse DFS (HR, 3.24; 95% CI, 2.12 to 4.95; P Ͻ .001; adjusted HR, 3.49; 95% CI, 2.19 to 5.54; P Ͻ .001; Fig 3) . A similar yet weaker association for the effect of N stage on DFS was observed among pMMR tumors (HR, 2.26; 95% CI, 1.93 to 2.63; P Ͻ .001; adjusted HR, 2.05; 95% CI, 1.74 to 2.41; P Ͻ .001; Fig 3) . Further analysis revealed a statistically significant interaction between MMR status and lymph node category (P interaction ϭ .0135).
Among patients with dMMR tumors, those with mutated versus wild-type BRAF had similar DFS rates (HR, 1.33; 95% CI, 0.87 to 2.04; Fig 4) . A similar outcome was also seen for dMMR tumors with mutated versus wild-type KRAS (Fig 4) . Among patients with pMMR tumors, mutated BRAF V600E was associated with significantly worse DFS (HR, 1.51; 95% CI, 1.19 to 1.92; P Ͻ .001; adjusted HR, 1.32; 95% CI, 1.01 to 1.73; P ϭ .044) compared with wild-type cases (Fig 4) . Similarly, pMMR tumors with mutated versus wild-type KRAS were associated with significantly poorer DFS (HR, 1.37; 95% CI, 1.17 to 1.60; P Ͻ .001; adjusted HR, 1.45, 95% CI, 1.22 to 1.73; P Ͻ .001; Fig 4) . However, neither the MMR by BRAF V600E (adjusted P ϭ .93) nor the MMR by KRAS (adjusted P ϭ .38) interaction tests were statistically significant. Compared with tumors with wild-type copies of both genes, those with mutation in either BRAF V600E or KRAS showed significantly worse DFS (Table 2 ; Appendix Figure A1 , online only).
Validation Cohort
We attempted to validate the interaction between MMR, tumor site, and nodal status in patients with stage III colon cancer from a phase III clinical trial of FU and leucovorin Ϯ irinotecan where no difference in survival by adjuvant treatment arm was found (CALGB 89803 trial). 27 Consistent with findings in our study cohort, a statistically significant interaction was observed between MMR status and tumor site for DFS (P interaction ϭ .037), adjusted for clinical factors but not BRAF V600E or KRAS status because mutation data were available in only 64% of patients in the validation cohort. The interaction for MMR and tumor site was similar and remained statistically significant when adjusting for an MMR and treatment arm interaction in addition to covariates. Among patients from the validation cohort with proximal cancers, dMMR was significantly associated with improved DFS (HR, 0.59; 95% CI, 0.41 to 0.86; P ϭ .0039) after adjusting for N category, T stage, histologic grade, age, sex, and study arm. Among distal cancers, DFS did not differ significantly by MMR status (adjusted HR, 1.58; 95% CI, 0.72 to 3.46; P ϭ .2817), although only 14 of 378 patients were in the distal dMMR subgroup. The statistically significant interaction between MMR and nodal status seen in our cohort was not confirmed in the validation cohort (adjusted P ϭ .7010). 
DISCUSSION
We determined the prognostic impact of MMR status in prospectively collected stage III colon cancers from patients treated in an adjuvant study of FOLFOX Ϯ cetuximab. 23 Study arms were combined for the analysis because the addition of cetuximab did not improve outcome and no interaction between treatment and any of the biomarkers was observed. Among 314 dMMR tumors (12%), 49% carried BRAF V600E mutations, and 10.6% had KRAS mutations. Although MMR status was not prognostic in the overall cohort, its association with DFS depended on tumor site as shown by a statistically significant interaction. Whereas dMMR versus pMMR was associated with a statistically significant DFS advantage in proximal tumors, dMMR was unexpectedly associated with worse DFS in distal tumors. Patients with distal (v proximal) dMMR tumors were significantly more likely to be younger (age 52 v 63 years, respectively; P Ͻ .001) and to have lower rates of mutation in BRAF V600E (20% v 54%, respectively; P Ͻ .001) but higher rates of mutation in KRAS (28% v 8%, respectively; P Ͻ .001). We validated our finding for the dependence of MMR on tumor site for DFS in an independent cohort of patients with stage III colon cancer randomly assigned to FU/leucovorin Ϯ irinotecan in another adjuvant trial (CALGB 89803 27 ). In that cohort, a statistically significant interaction was also found between MMR and tumor site for DFS. Taken together, these data indicate that the tumor site dependence of MMR for prognosis seems unrelated to the chemotherapy regimen used but is likely a result of intrinsic biologic factors.
We found a similar frequency of N2 disease in dMMR and pMMR tumors that was unexpected because dMMR has been consistently associated with lower tumor stage at diagnosis and is uncommon in advanced CRCs. 16, [24] [25] [26] In our cohort, a statistically significant interaction was found between MMR and nodal category for their impact on DFS. N2 versus N1 tumors showed significantly worse outcome in both dMMR and pMMR tumors, with a stronger effect in the former. This interaction, however, was not validated in the independent cohort. Although this may be related to an inability to adjust for BRAF V600E and KRAS status, which was not available in the full validation cohort, 31,32 we did validate the interaction between MMR and tumor site despite this limitation.
The lack of association of MMR status with DFS in the overall cohort deserves comment. Most prior studies examining the prognostic impact of MMR have not adjusted for BRAF V600E or KRAS status. Furthermore, we identified poor prognostic subgroups among dMMR tumors (ie, distal and N2 tumors). Although our cohort was restricted to stage III cancers, studies demonstrating a favorable outcome for dMMR versus pMMR colon cancers have generally combined stage II and III tumors, [14] [15] [16] [17] 25, 27 suggesting that the favorable survival impact of dMMR may be stronger in earlier stage disease. 16, 25, 37 Another factor is treatment with the FOLFOX regimen because, in contrastwithFU, 19 oxaliplatinchemotherapysensitivityseemstobeindependent of the MMR system because oxaliplatin forms platinum adducts with DNA that cannot be repaired in MMR-deficient cells. 22 A study in stage II and III colon cancers (National Surgical Adjuvant Breast and Bowel Project C-07) found that the survival benefit of adding oxaliplatin to adjuvant FU/leucovorin was unrelated to MMR status. 38 Therefore, a survival benefit from oxaliplatin in both dMMR and pMMR tumors could attenuate any prognostic difference based on MMR status.
Although BRAF V600E mutations are strongly associated with dMMR, BRAF V600E mutations were significantly more frequent in N2 versus N1 cancers. In the overall cohort, BRAF V600E and KRAS mutations were each independently associated with a statistically significant reduction in DFS compared with wild-type tumors. When analyzed by MMR status, the prognostic impact of BRAF V600E or KRAS was limited to pMMR tumors, although the dMMR subgroups were admittedly smaller and the interaction test was not significant. In FOLFOX-treated stage III patients, our data indicate that any favorable impact of dMMR is restricted to proximal tumors or those that are N1. Dependence of the prognostic impact of MMR status on primary tumor site has implications for risk stratification and clinical decision making, particularly if our findings are found to apply to patients with stage II colon cancer. The potential for more selective use of adjuvant chemotherapy in patients with stage III disease does exist, as suggested by data from the Pan-European Trials in Adjuvant Colon Cancer-3 trial where a recursive partitioning analysis identified a tumor subgroup with dMMR and intact SMAD4 expression that had a clinical outcome similar to patients with stage II disease.
40,41 Strengths of our study include the prospective analysis of MMR and molecular markers using uniform assay methodology in a Clinical Laboratory Improvement Amendments-certified laboratory at a single tertiary medical center. We report the largest number of dMMR tumors from a single clinical trial. Study limitations include the limited median follow-up time of 4.1 years, although 3-year DFS has been shown to be a reliable surrogate for 5-year overall survival in adjuvant studies in colon cancer.
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In conclusion, the prognostic impact of dMMR on DFS was dependent on the primary tumor site in patients with stage III colon cancer, and this finding was validated in an independent cohort. Poor prognostic subgroups were observed within dMMR cancers that included distal site and N2 disease, which may have contributed to the nonsignificant overall impact of dMMR on DFS. Mutations in BRAF V600E or KRAS were each independently associated with reduced DFS and may therefore provide clinically useful prognostic information in FOLFOX-treated patients. 
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